🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the battle against superbug strains of the pathogen, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are increasing around the world, with data suggesting in excess of 82 million infections each year. Particularly high rates are reported in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the context of growing infection rates, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Medical experts are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Gain Clearance

Zoliflodacin, marketed under the name a brand name, was approved by the US FDA in mid-December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is employed against urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP collaborated with the drug firm Innoviva to bring it to fruition.

“This authorization marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing medical innovation.”

Testing Data and Global Access

Based on findings released by a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which involves a dual-drug approach. The research involved over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Medical professionals directly involved have shared optimism. The availability of a one-pill regimen like this is described as a "critical tool" for managing the epidemic. This is viewed as vital to alleviate the strain of the illness for people and to halt the transmission of untreatable gonorrhoea around the world.